Nerve pain drug duloxetine tested to stop pancreatitis after ERCP
NCT ID NCT06860984
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether the nerve pain medication duloxetine can prevent pancreatitis, a serious complication that sometimes occurs after an ERCP procedure. Researchers will give duloxetine or a placebo to 44 adults with biliary disease before their ERCP. The main goal is to see if fewer people develop pancreatitis in the duloxetine group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- duloxetine
- What this could lead to
- If it works, this could offer a simple, non-opioid way to prevent a common and serious complication after ERCP.
- What could go wrong
- This is a small, early-phase trial with only 44 participants, so results may not apply to everyone. Duloxetine also has side effects like nausea and dizziness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta Unuversity
RECRUITINGTanta, 31527, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.